On Monday, Exact Sciences received an upgrade to its Relative Strength (RS) Rating, from 79 to 83.
Risk Management In The Stock Market: How Much Money To Invest Now
This unique rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history shows that the best-performing stocks tend to have an 80 or higher RS Rating as they launch their biggest climbs.
Exact Sciences is trying to complete a with a 72.83 entry. See if the stock can clear the breakout price in volume at least 40% above average.
The company reported 0% EPS growth in the latest quarterly report. Revenue increased 11%.
Exact Sciences holds the No. 35 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
